Tyrosine hydroxylase, interleukin-1β and tumor necrosis factor-α are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis

Psychiatry Research

Volumn 176, Issue 1, 2010, Pages 1-7

  Liu, Liang ^a   Jia, Fujun ^b   Yuan, Guozhen ^a   Chen, Zaohuo ^a   Yao, Jianjun ^a   Li, Hengfen ^c   Fang, Chunxia ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Guangdong Provincial Cardiovascular Institute   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Gene expression; Interleukin 1 ; PANSS; Schizophrenia; Tumor necrosis factor ; Tyrosine hydroxylase

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOPATHOGENESIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SCORING SYSTEM; SIBLING;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MALE; PSYCHIATRIC STATUS RATING SCALES; RNA, MESSENGER; SCHIZOPHRENIA; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE; YOUNG ADULT;

EID: 76749104706     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.10.024     Document Type: Article

References (81)

1. Abreu P., Llorente E., Hernandez M.M., and Gonzalez M.C. Interleukin-1 beta stimulates tyrosine hydroxylase activity in the median eminence. Neuroreport 5 (1994) 1356-1358
2. Akil M., Edgar C.L., Pierri J.N., Casali S., and Lewis D.A. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biological Psychiatry 47 (2000) 361-370
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiology of Aging 21 (2000) 383-421
4. Al-Omaishi J., Bashir R., and Gendelman H.E. The cellular immunology of multiple sclerosis. Journal of Leukocyte Biology 65 (1999) 444-452
5. Andreasen N.C., Endicott J., Spitizer R.L., and Winokur G. The family history method using diagnostic criteria: reliability and validity. Archives of General Psychiatry 34 (1977) 1229-1235
6. Andreasen N.C., Flaum M., and Arndt S. The Comprehensive Assessment of Symtoms and History (CASH). An instrument for assessing diagnosis and paychopathology. Archives of General Psychiatry 49 (1992) 615-623
7. Angrist B., and Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Advances in Biochemical Psychopharmacology 16 (1977) 677-680
8. Anisman H., Merali Z., Poulter M.O., and Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Current Pharmaceutical Design 11 (2005) 963-972
9. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., and Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. The Journal of Biological Chemistry 279 (2004) 51647-51653
10. Arolt V., Rothermundt M., Wandinger K.P., and Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry 5 (2000) 150-158
11. Baker I., Masserano J., and Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophrenia Research 20 (1996) 199-203
12. Barak V., Barak Y., Levine J., Nisman B., and Roisman I. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. Journal of Basic and Clinical Physiology and Pharmacology 6 (1995) 61-69
13. Bhatt S., and Siegel A. Potentiating role of interleukin 2 (IL-2) receptors in the midbrain periaqueductal gray (PAG) upon defensive rage behavior in the cat: role of neurokinin NK(1) receptors. Behavioural Brain Research 167 (2006) 251-260
14. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Wagner R.L., and Yolken R.H. Maternal cytokine levels during pregnancy and adult psychosis. Brain, Behavior, and Immunity 15 (2001) 411-420
15. Carlsson A., and Carlsson M.L. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues in Clinical Neuroscience 8 (2006) 137-142
16. Carvey P.M., Chen E.Y., Lipton J.W., Tong C.W., Chang Q.A., and Ling Z.D. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. Journal of Neural Transmission 112 (2005) 601-612
17. Cosentino M., Fietta A.M., Ferrari M., Rasini E., Bombelli R., Carcano E., Saporiti F., Meloni F., Marino F., and Lecchini S. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109 (2007) 632-642
18. Crespo-Facorro B., Carrasco-Marin E., Perez-Iglesias R., Pelayo-Teran J.M., Fernandez-Prieto L., Leyva-Cobian F., and Vazquez-Barquero J.L. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Research 158 (2008) 206-216
19. Danis V.A., Millington M., Hyland V.J., and Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clinical and Experimental Immunology 99 (1995) 303-310
20. Djoba Siawaya J.F., Roberts T., Babb C., Black G., Golakai H.J., Stanley K., Bapela N.B., Hoal E., Parida S., van Helden P., and Walzl G. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS ONE 3 (2008) e2535
21. Ebrinc S., Top C., Oncul O., Basoglu C., Cavuslu S., and Cetin M. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. The Journal of International Medical Research 30 (2002) 314-317
22. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., and Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators of Inflammation 10 (2001) 109-115
23. Ferrari C.C., Pott Godoy M.C., Tarelli R., Chertoff M., Depino A.M., and Pitossi F.J. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiology of Disease 24 (2006) 183-193
24. Fertuzinhos S.M., Oliveira J.R., Nishimura A.L., Pontual D., Carvalho D.R., Sougey E.B., Otto P.A., and Zatz M. Analysis of IL-1alpha, IL-1beta, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia. Journal of Molecular Neuroscience 22 (2004) 251-256
25. Franceschi C., Bonafe M., Valensin S., Olivieri F., De Luca M., Ottaviani E., and De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences 908 (2000) 244-254
26. Halford W.P. The essential prerequisites for quantitative RT-PCR. Nature Biotechnology 17 (1999) 835
27. Hanninen K., Katila H., Rontu R., Mattila K.M., Hurme M., and Lehtimaki T. Tumor necrosis factor-alpha -G308A polymorphism in schizophrenia in a Finnish population. Neuroscience Letters 385 (2005) 76-81
28. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Annals of the New York Academy of Sciences 991 (2003) 214-228
29. Hori H., Yoshimura R., Yamada Y., Ikenouchi A., Mitoma M., Ida Y., and Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. International Clinical Psychopharmacology 22 (2007) 21-27
30. Ichinose H., Ohye T., Fujita K., Pantucek F., Lange K., Riederer P., and Nagatsu T. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 8 (1994) 149-158
31. Ito R., Asami S., Kagawa S., Motohashi S., Shichino H., Chin M., Yoshida Y., Nemoto N., Mugishima H., and Suzuki T. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma. Biological & Pharmaceutical Bulletin 27 (2004) 315-318
32. Jacewicz R., Szram S., Galecki P., and Berent J. Will genetic polymorphism of tetranucleotide sequences help in the diagnostics of major psychiatric disorders?. Forensic Science International 162 (2006) 24-27
33. Jarskog L.F., Xiao H., Wilkie M.B., Lauder J.M., and Gilmore J.H. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. International Journal of Developmental Neuroscience 15 (1997) 711-716
34. Jiang J.L., Qiu Y.H., Peng Y.P., and Wang J.J. Immunoregulatory role of endogenous catecholamines synthesized by immune cells. Sheng Li Xue Bao 58 (2006) 309-317
35. Jin G., Tan X., Tian M., Qin J., Zhu H., Huang Z., and Xu H. The controlled differentiation of human neural stem cells into TH-immunoreactive (ir) neurons in vitro. Neuroscience Letters 386 (2005) 105-110
36. Johnson J.D., Campisi J., Sharkey C.M., Kennedy S.L., Nickerson M., Greenwood B.N., and Fleshner M. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135 (2005) 1295-1307
37. Kapsimalis F., Richardson G., Opp M.R., and Kryger M. Cytokines and normal sleep. Current Opinion in Pulmonary Medicine 11 (2005) 481-484
38. Katila H., Appelberg B., Hurme M., and Rimon R. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophrenia Research 12 (1994) a29-34
39. Katila H., Hanninen K., and Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Molecular Psychiatry 4 (1999) 179-181
40. Kavelaars A., van Der Voort C.R., and Heijnen C.J. Adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension 34 (1999) e5
41. Khan M.M., Sansoni P., Silverman E.D., Engleman E.G., and Melmon K.L. Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochemical Pharmacology 35 (1986) 1137-1142
42. Kiecolt-Glaser J.K., and Glaser R. Depression and immune function: central pathways to morbidity and mortality. Journal of Psychosomatic Research 53 (2002) 873-876
43. Kim H.Y., and Rikihisa Y. Expression of interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in human peripheral blood leukocytes exposed to human granulocytic ehrlichiosis agent or recombinant major surface protein P44. Infection and Immunity 68 (2000) 3394-3402
44. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., and Leonard B.E. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28 (2004) 1129-1134
45. Kurumaji A., Kuroda T., Yamada K., Yoshikawa T., and Toru M. An association of the polymorphic repeat of tetranucleotide (TCAT) in the first intron of the human tyrosine hydroxylase gene with schizophrenia in a Japanese sample. Journal of Neural Transmission 108 (2001) 489-495
46. Larson S.J. Behavioral and motivational effects of immune-system activation. The Journal of General Psychology 129 (2002) 401-414
47. Levine S.Z., and Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. Journal of Clinical Psychopharmacology 27 (2007) 431-436
48. Lindenmayer J.P., Bernstein-Hyman R., and Grochowski S. A new five factor model of schizophrenia. The Psychiatric Quarterly 65 (1994) 299-322
49. Lipska B.K., Lerman D.N., Khaing Z.Z., and Weinberger D.R. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. The European Journal of Neuroscience 18 (2003) 3097-3104
50. Mallet J. The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. Trends in Neurosciences 19 (1996) 191-196
51. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?. Federation Proceedings 32 (1973) 200-205
52. Melchitzky D.S., and Lewis D.A. Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology 22 (2000) 466-472
53. MohanKumar S.M., and MohanKumar P.S. Systemic Interleukin-1beta stimulates the simultaneous release of norepinephrine in the paraventricular nucleus and the median eminence. Brain Research Bulletin 65 (2005) 451-456
54. Monteleone P., Fabrazzo M., Tortorella A., and Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Research 71 (1997) 11-17
55. Morar B., Schwab S.G., Albus M., Maier W., Lerer B., and Wildenauer D.B. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics 144B (2006) 318-324
56. Müller N., and Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 22 (1998) 1-33
57. Muller N., Riedel M., Gruber R., Ackenheil M., and Schwarz M.J. The immune system and schizophrenia. An integrative view. Annals of the New York Academy of Sciences 917 (2000) 456-467
58. Mullington J.M., Hinze-Selch D., and Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Annals of the New York Academy of Sciences 933 (2001) 201-210
59. Musso N.R., Brenci S., Setti M., Indiveri F., and Lotti G. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. The Journal of clinical Endocrinology and Metabolism 81 (1996) 3553-3557
60. Naudin J., Capo C., Giusano B., Mege J.L., and Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophrenia Research 26 (1997) 227-233
61. Pae C.U., Kim J.J., Serretti A., Lee C.U., Lee S.J., Lee C., and Paik I.H. VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. Neuropsychobiology 47 (2003) 131-136
62. Papiol S., Rosa A., Gutierrez B., Martin B., Salgado P., Catalan R., Arias B., and Fananas L. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. Journal of Medical Genetics 41 (2004) 219-223
63. Pochet R., Delespesse G., Gausset P.W., and Collet H. Distribution of beta-adrenergic receptors on human lymphocyte subpopulations. Clinical and Experimental Immunology 38 (1979) 578-584
64. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., and Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 63 (2008) 801-808
65. Qiu Y.H., Peng Y.P., Jiang J.M., and Wang J.J. Expression of tyrosine hydroxylase in lymphocytes and effect of endogenous catecholamines on lymphocyte function. Neuroimmunomodulation 11 (2004) 75-83
66. Qiu Y.H., Cheng C., Dai L., and Peng Y.P. Effect of endogenous catecholamines in lymphocytes on lymphocyte function. Journal of Neuroimmunology 167 (2005) 45-52
67. Rodriguez-Pallares J., Guerra M.J., and Labandeira-Garcia J.L. Angiotensin II and interleukin-1 interact to increase generation of dopaminergic neurons from neurospheres of mesencephalic precursors. Brain research. Developmental Brain Research 158 (2005) 120-122
68. Roiz-Santianez R., Crespo-Facorro B., Perez-Iglesias R., Pelayo-Teran J.M., Carrasco-Marin E., Mata I., Sanchez E., Leyva-Cobian F., and Vazquez-Barquero J.L. Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Research 162 (2008) 167-171
69. Sanders V.M., Baker R.A., Ramer-Quinn D.S., Kasprowicz D.J., Fuchs B.A., and Street N.E. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. Journal of Immunology 158 (1997) 4200-4210
70. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., and Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse 60 (2006) 319-346
71. Solfrizzi V., D'Introno A., Colacicco A.M., Capurso C., Todarello O., Pellicani V., Capurso S.A., Pietrarossa G., Santamato V., Capurso A., and Panza F. Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta; International Journal of Clinical Chemistry 364 (2006) 91-112
72. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. Journal of Neurochemistry 96 (2006) 706-718
73. Steiner A.A., Chakravarty S., Robbins J.R., Dragic A.S., Pan J., Herkenham M., and Romanovsky A.A. Thermoregulatory responses of rats to conventional preparations of lipopolysaccharide are caused by lipopolysaccharide per se - not by lipoprotein contaminants. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 289 (2005) R348-R352
74. Stone J.M., Morrison P., and Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. Journal of Psychopharmacology 21 (2007) 440-452
75. Watkins L.R., Milligan E.D., and Maier S.F. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Advances in Experimental Medicine and Biology 521 (2003) 1-21
76. Weickert C.S., Webster M.J., Gondipalli P., Rothmond D., Fatula R.J., Herman M.M., Kleinman J.E., and Akil M. Postnatal alterations in dopaminergic markers in the human prefrontal cortex. Neuroscience 144 (2007) 1109-1119
77. Wei J., Ramchand C.N., and Hemmings G.P. Association of polymorphic VNTR region in the first intron of the human TH gene with disturbances of the catecholamine pathway in schizophrenia. Psychiatric Genetics 5 (1995) 83-88
78. Wei J., Ramchand C.N., Clark A.E., and Hemmings G.P. A study of enzymes involved in catecholamine metabolism in parents of patients with schizophrenia. Schizophrenia Research 19 (1996) 27-32
79. Wieseler-Frank J., Maier S.F., and Watkins L.R. Central proinflammatory cytokines and pain enhancement. Neurosignals 14 (2005) 166-174
80. Xu H.M., Wei J., and Hemmings G.P. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. The British Journal of Psychiatry: The Journal of Mental Science 164 (1994) 251-253
81. Zai G., Muller D.J., Volavka J., Czobor P., Lieberman J.A., Meltzer H.Y., and Kennedy J.L. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology 188 (2006) 171-182